Pamela Rath, MD
Ophthalmology · Pittsburgh, PANPI 1659356327
Payments from drug & device makers
Across 101 payments — averaging $91.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Immunocore Limited$3K
- Bausch & Lomb Americas Inc.$3K
- Regeneron Healthcare Solutions, Inc.$2K
- Apellis Pharmaceuticals, Inc.$350
- Harrow Eye, LLC$228
- Genentech USA, Inc.$187
- plus $837 from 13 others
What the payments were for
- Consulting fees$2,60028%
- Speaking & faculty fees$3,15034%
- Food & beverage$3,50638%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Immunocore Limited | 4 | $3,388 |
| Bausch & Lomb Americas Inc. | 4 | $2,565 |
| Regeneron Healthcare Solutions, Inc. | 44 | $1,702 |
| Apellis Pharmaceuticals, Inc. | 13 | $350 |
| Harrow Eye, LLC | 2 | $228 |
| Genentech USA, Inc. | 8 | $187 |
| Astellas Pharma US Inc | 4 | $170 |
| Novartis | 8 | $167 |
| Sandoz | 1 | $150 |
| Spark Therapeutics, Inc. | 1 | $104 |
| AbbVie | 2 | $65 |
| Alimera Sciences, Inc. | 2 | $36 |
| Sun Pharmaceutical Industries Inc. | 2 | $29 |
| Dompe US, Inc. | 1 | $28 |
| Genentech, Inc. | 1 | $25 |
| Tarsus Pharmaceuticals, Inc. | 1 | $17 |
| Quidel Corporation | 1 | $17 |
| Biotissue Holdings Inc. | 1 | $15 |
| Oyster Point Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,256 in reported general payments places this provider in the 80th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 107 | $5,144 |
| Brimonidine Tartrate | 44 | $4,321 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 18 | $2,827 |
| Ketorolac Tromethamine | 87 | $1,190 |
| Timolol Maleate | 50 | $1,027 |
| Dorzolamide Hcl | 39 | $797 |
| Latanoprost | 59 | $750 |
| Atropine Sulfate | 12 | $407 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 20 | $302 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Pittsburgh
- Francis MahPittsburgh$1.2M
- Robert NoeckerPittsburgh$634K
- Srinivas KondapalliPittsburgh$215K
- Deepinder DhaliwalPittsburgh$170K
- Deval ParanjpePittsburgh$121K
- Ian ConnerPittsburgh$103K
- Vishal JhanjiPittsburgh$80K
- David AlmeidaErie$6.3M
- William ChristieCranberry Township$5.2M
- Carl RegilloPlymouth Meeting$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.